Table 1. Patient clinical data.

Flucon = fluconazole, itracon = itraconazole, amph sus = amphotericin suspension (10 mg/ml swirl and swallow 4x daily). All swabs were taken for routine Dg purposes. Ethical approval was obtained under the Newcastle Autoimmune Inflammatory Rheumatic Disease Research Biobank (NAIRB) Ref No NAIRB-DL-01 dx obtained from the Southwest 3 Research Ethics Committee (Ref. 10/H0106/30) to perform research on samples collected as part of the NAIRB by researchers based at Newcastle University. Pts 1–5 had primary CMC; whole exome sequencing confirmed gain-of-function STAT1 mutations in 3 while no mutation was identified in 2 patients; P4 had candida granuloma of soft palate. P6 had 2oCMC due to steroid inhalers (asthma). Swabs were processed in the Department of Microbiology, Newcastle upon Tyne Hospitals NHS Trust (NUTH): Mohammad Raza, Consultant Microbiologist (Muhammad.Raza@nuth.nhs.uk) and Claire Rennison, Senior BMS (now retired).

Pt No	M/F	age	Diagnosis	onset of CMC	Swab date	Candida spp. Identified	Prescribed
1	F	64	1oCMC (GOF-STAT1)	adolescence	14/11/2011	C. albicans + C. nivariensis	Flucon 100 mg/d
					16/04/2012	C. albicans	Itracon 100 mg/d
					09/07/2012	C. albicans	Flucon 100 mg/d
					14/01/2013	C. albicans	Flucon 100 mg/d
2	F	42	1oCMC (GOF-STAT1)	adolescence	13/02/2012	C. albicans	Flucon 100 mg/d
3	M	43	1oCMC (GOF-STAT1)	early childhood	09/07/2012	C. albicans	Flucon 100 mg/d
					10/09/2012	C. albicans	Itracon 100 mg/d
					12/11/2012	C. albicans	Itracon 100 mg/d
					13/01/2014	C. albicans	Itracon 100 mg/d + amph sus 10 mg/ml x4/d
4	F	61	1oCMC (granuloma)	10 yrs ago	13/02/2012	C. albicans	Flucon 100 mg/d;7 days each month
5	M	30	1oCMC (GOF-STAT1)	early childhood	14/05/2012	C. albicans	Flucon 100 mg/d
6	F	43	2o CMC (steroid inhalers)	8yrs ago	12/11/2012	C. albicans	Itracon 100 mg/d
					08/03/2013	C. albicans	amph sus 10 mg/ml x4/d